HOME >> BIOLOGY >> NEWS
Doctors failure to reevaluate asthma severity hurts wheezing sufferers

Doctors who do not periodically reevaluate their patients' asthma severity are failing to provide good care to asthma sufferers, report Johns Hopkins physicians May 20 at the American Thoracic Society's annual meeting.

"We found that doctors were not reevaluating their patient's underlying asthma severity estimates and that these estimates anchor their treatment decisions," says Gregory Diette, M.D., an assistant professor of pulmonary and critical care medicine at Hopkins. "Doctors need to frequently update their severity assessments in order to provide care that meets the patient's needs."

According to most treatment guidelines, doctors should base asthma therapy on an individual's symptoms prior to medication use, a profile known as underlying severity estimate. But how physicians' estimates influenced care has been a black box. To examine the issue, the Hopkins team gathered data from 1,510 patients who had moderate asthma, as determined by self-reported symptoms and treatment guidelines. Through surveys, they discovered that their doctors had classified 849 of them as having an underlying severity estimate of mild; they deemed the other 761 as moderate or greater.

When the researchers compared the two groups with National Asthma and Education Prevention Program (NAEPP) guidelines, they found that the lower the estimate, the worse the care. Doctors gave many more moderately asthmatic patients guidance and information about how to manage their symptoms and handle an attack, in comparison to mild asthmatics. Roughly 60 percent of the moderate cases, for example,had a peak flow meter, a device patients use frequently to measure lung capacity and adjust anti-asthma drugs to prevent severe episodes. Only 16 percent of the mildly asthmatic patients owned these devices.

"Doctors need to reevaluate patients periodically to ensure an accurate, up-to-date diagnosis, and ensure quality treatment," says Linda Wolfenden, M.D., presenter of the study
'"/>

Contact: Kate O'Rourke
korourke@jhmi.edu
410-955-8665
Johns Hopkins Medical Institutions
19-May-2001


Page: 1 2

Related biology news :

1. Doctors miss chances to help pregnant women quit smoking
2. Doctors miss chance to advise women of vitamin that prevents birth defects, survey finds
3. Doctors perform more IVF treatments, but multiple births decline
4. Doctors aware of Tylenol-related liver risk - but is the public getting the message?
5. One In Three Doctors Recommends Herbal Supplements To Patients
6. Doctors Find Lead On Common Genes Which Can Lead To Bowel Cancer
7. Plant Doctors Find Genetic Solution For Papaya Growers
8. Phase Out Planned For One Of Top Five U.S. Pesticides, Plant Doctors Respond
9. New Heart-Attack Indicator Dramatically Improves Diagnostic Accuracy Of ER Doctors: TnT/Echocardiogram Combination Could Reduce Needless Admissions
10. Pump failure implicated in a form of dystonia
11. UCSD finds genetic time bomb in heart that leads to heart failure in some patients

Post Your Comments:
(Date:5/19/2015)... Research and Markets ( ... the  "Genetic Testing Market Outlook 2018"  report ... ,A recent report, Genetic Testing Market Outlook ... current and future genetic testing market. A ... principles and types are covered in this ...
(Date:5/14/2015)... 14, 2015  Verificient Technologies, Inc., a ... online remote proctoring, announced a new alliance ... and creator of the Canvas Learning Management ... companies will benefit from the seamless integration ... As a fully integrated multifactor biometrics behavioral ...
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, a ... start of a new Phase III double blind, randomized, ... novel formulation, CM-AT, on all children ages 3-8 with ... FDA Phase III double blinded clinical trial for CM-AT ... levels of the digestive enzyme chymotrypsin. This new trial ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
(Date:5/21/2015)... 21, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... medicine company focused on the development of autologous ... at the International Society for Cellular Therapy (ISCT) ... tendinosis currently in a Phase 1/2 clinical trial.  ... from 5:30 PM to 7:00 PM local ...
(Date:5/21/2015)... Prussia, PA (PRWEB) May 21, 2015 ... O’Neill has joined the firm as senior statistician and ... 30 years of experience in the management and analysis ... biologics, pharmaceutical and chemical industries. , “We’re delighted to ... longstanding capabilities in data analytics,” said Dr. Philippe Cini, ...
(Date:5/20/2015)... and Markets ( http://www.researchandmarkets.com/research/x4b7kw/top_technologies ) has announced ... Insights" report to their offering. Technical ... the Health and Wellness sector and has identified top ... in the year 2015. The research service provides an ... wellness technologies that are anticipated to have the highest ...
(Date:5/20/2015)... DUBLIN , May 19, 2015 Research and ... addition of the "Global Cell Therapy Market Outlook ... Utilization of cell therapy in tissue and regenerative medicine ... are no other options which could help in the ... in this segment but they are unable to form ...
Breaking Biology Technology:RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Top Technologies in the Health and Wellness Industry 2015 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
Cached News: